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ABSTRACT
Venous thromboembolism can occur in up to 84% of 
cases following total joint replacement. It can result 
in pain, swelling, chronic post-thrombotic syndrome, 
and pulmonary embolism. Its prevention is vital 
to the success of the surgery. To achieve a safe and 
effective prophylaxis, a combination of mechanical 
and pharmacologic agents should be used. New 
generation of thromboprophylactic agents target 
different factors of the coagulation pathway. 
Key words: arthroplasty, replacement, hip; arthroplasty, 
replacement, knee; postthrombotic syndrome; 
pulmonary embolism; venous thromboembolism
introduction
Venous thromboembolism (VTE) includes conditions 
from asymptomatic deep vein thrombosis (DVT) to 
fatal pulmonary embolism (PE). DVT of popliteal 
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and femoral veins (proximal DVT) is clinically 
more significant than that of calf veins (distal DVT). 
Proximal DVT is associated with a higher frequency 
of PE.1 Distal DVT rarely causes PE, unless it extends 
to proximal veins.2 Asymptomatic distal DVT can 
be associated with post-thrombotic syndrome and 
recurrent DVT. VTE can occur spontaneously or 
secondary to coagulation disorders or lower limb 
surgery. This study reviews the clinical presentation, 
pathogenesis, prophylaxis, and management of 
VTE after total hip replacement (THR) or total knee 
replacement (TKR).
clinical presentation and diagnosis
Clinical features of DVT following total joint 
replacement are typically non-specific. Individual 
symptoms per se do not reliably predict DVT.3 
Thigh and calf swelling, especially calf swelling by 
>3 cm, is the most usual presentation. Symptoms 
of DVT include swelling (85%), pain (78%), positive 
Homen’s sign (56%), erythema (24%), and fever 
(5%).4,5 Venography is considered the gold standard 
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for investigation, but it is invasive and involves 
exposure to contrast media and radiation.6 Doppler 
ultrasonography is non-invasive and has near 100% 
sensitivity in the detection of proximal DVT.7 
 Symptoms of PE include shortness of breath 
(70%), tachycardia (43%), hypoxia (18%), and 
hypotension (10%).8 Many patients also complain of 
chest pain. Pulmonary angiography is considered the 
gold standard for diagnosing pulmonary embolism, 
but it is invasive and may cause serious complications 
(cardiac arrhythmia or even cardiac perforation).9 
Contrast helical computed tomographic angiography 
of the thorax is non-invasive, more readily available, 
and has up to 90% sensitivity and 95% specificity in 
the detection of PE.10
 The probability for detecting PE using 
ventilation-perfusion scanning depends on the 
degree of ventilation-perfusion mismatch. It is an 
imaging option for PE and is most helpful when the 
result is normal, which rules out the diagnosis. For 
more than half of the patients, the probability is either 
intermediate (in which 30% have PE) or low (in which 
14% have PE). Thus ventilation-perfusion scanning 
is frequently non-diagnostic and inconclusive.11 
For patients in shock in whom PE is suspected, 
bedside echocardiography may be an appropriate 
investigative tool.12
incidence and risK factors
The incidence of DVT is 39 to 74% following THR 
and 1 to 84% following TKR.13,14 Such a wide 
range is due to different investigative tools used 
to identify thrombosis. Venography and Doppler 
ultrasonography typically record higher rates of VTE. 
Symptoms are present in only a small proportion of 
VTE patients. According to the Scottish Arthroplasty 
Registry, the incidence of clinically significant VTE 
within 3 months of THR and TKR is 2.27 and 1.79%, 
respectively, whereas that of fatal PE is 0.22 and 
0.15%, respectively.15
 VTE was thought to be less common in Asians 
than Caucasians, owing to the rarity of the Factor 
V Leiden trait in non-Caucasians.16,17 The rate of 
VTE after major orthopaedic surgery is low in 
Asians.18 However, in the SMART venography study 
including 326 patients undergoing THR or TKR in 
3 Asian countries, the rate of asymptomatic VTE 
detected by venography was 36.5%.19 Similarly, the 
VTE rate was 33.8% after THR and 65.3% after TKR 
in Japanese populations,20 and was 41% after TKR 
in Korean populations.21 These studies showed that 
the rates of VTE in Asian populations are actually 
comparable to those of Caucasians. Other unknown 
genetic or environmental factors (e.g. genetic loci for 
protein S, protein C, and antithrombin deficiencies) 
may be responsible for the occurrence of VTE in non-
Caucasian populations.22
 Haemostasis (normal coagulation cascade) is 
essential for human survival (Fig.). The aetiology of 
VTE depends on the pathological triad of venous 
stasis, hypercoagulability, and trauma.23 Prolonged 
bedrest, presence of malignancy, use of contraceptive 
pills, hypercoagulable states, and a history of DVT 
are risk factors. THR and TKR can cause venous 
stasis and endothelial injury in the lower limb.24 
Other factors that increase the risk (in THR patients) 
include age >70 years, primary osteoarthritis as the 
indication for surgery, operation through the lateral 
approach, and undertransfusion of blood.25 Regional 
anaesthesia and rheumatoid arthritis patients have 
lower relative risks for VTE.25,26
Figure Coagulation	 cascade	 and	 the	 sites	 of	 action	 of	
commonly	used	anticoagulants.
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treatMent 
The goals of treatment are to prevent propagation 
of thrombus, restore venous patency, prevent PE, 
and decrease the risk of post-thrombotic syndrome 
(persistent leg swelling, dermatitis, recurrent 
cellulitis, and ulceration). Low-molecular-weight 
heparin (LMWH) and compression stocking are 
commonly used to control lower-limb swelling.27 
Warfarin is started at the same time and titrated until 
the international normalised ratio (INR) is in the 
range of 2 to 3. The LMWH can then be stopped and 
warfarin can be continued for at least 3 months. The 
duration of anticoagulation is controversial; a period 
of 3 months is considered adequate in patients with 
THR or TKR as the only identifiable risk factor.28,29 
Anticoagulation therapy for PE should be started as 
soon as possible.30,31 Selected patients with massive PE 
and haemodynamic instability may be candidates for 
intra-arterial thrombolysis or surgical embolectomy. 
In patients already receiving anticoagulation or those 
contraindicated to anticoagulation, insertion of an 
inferior vena cava filter should be considered when 
PE occurs.
prophylaXis
All patients undergoing THR or TKR should receive 
some form of mechanical and/or pharmacological 
prophylaxis. The effectiveness of various prophylactic 
agents is difficult to compare. Fatal PE is so rare 
that even large trials (e.g. the RECORD trial for 
rivaroxaban32) may not have adequate power to 
detect any difference. Joint registries can provide 
large numbers of patients for analysis, but cannot 
establish causal relationships.
 In addition, many studies are funded by 
pharmaceutical companies and may involve conflicts 
of interest. For example, the Asia-Pacific Thrombosis 
Advisory Board meeting and consensus statements 
were sponsored by the Bayer Schering Pharma AG.33
 Two of the most influential guidelines for 
thromboprophylaxis are those of the American 
College of Chest Physician (ACCP) and the American 
Academy of Orthopaedic Surgeons (AAOS). Both 
are based on systematic reviews of the literature and 
have been regularly renewed. The first edition of the 
AAOS guideline was published in 2008,34 in response 
to the seventh edition of the ACCP guideline in 
2004.35 The ACCP published its ninth edition in 
2011,36 and the AAOS published its second edition 
in 2012.37 Deviation from the guideline is sometimes 
needed for individual patients. It is more important 
to understand the rationale behind the guideline 
than to follow it blindly. Thus, the ACCP and AAOS 
guidelines can be regarded as complementing each 
other.
Mechanical prophylaxis
The AAOS recommended that mechanical 
prophylaxis be started early and continued until 
discharge. Patients should also be mobilised as 
soon as feasible.37 The ACCP also supported the use 
of intermittent pneumatic compression devices.36 
Mechanical prophylaxis includes graduated 
compression stocking, intermittent calf compression, 
foot pump, and early mobilisation. These act by 
increasing the velocity of venous blood flow and 
preventing stasis,38,39 as well as decreasing the 
coagulability of blood by stimulating fibrinolysis.40 
 Graduated compression stocking is easy to 
apply. It can reduce the probability of DVT to 39% 
from 50%.41 It reduces the relative risk of developing 
DVT by 25%.42 Nonetheless, it is much less effective 
than anticoagulants or other mechanical prophylaxis 
devices such as intermittent calf compression. 
Therefore, it is not recommended as the sole 
prophylactic measure. 
 Intermittent calf compression can reduce 
the probability of DVT to 22% and the relative 
risk by 60%.41–43 Nonetheless, it is also inferior to 
anticoagulants (LMWH and warfarin) for preventing 
proximal DVT.13
 The use of the foot pump can decrease the 
rate of DVT in THR and TKR patients.44–47 Active 
mobilisation exercises of the foot and ankle can 
increase venous flow,38,39 but their effectiveness as a 
prophylactic measure is unknown.
 Mechanical prophylaxis has a low risk of 
bleeding complication and enhances the effectiveness 
of anticoagulants. Although it may result in rare 
complications such as peroneal nerve palsy and 
compartment syndrome,48,49 it is in general very safe. 
The main factor limiting its efficacy is patient non-
compliance, which is around 3 to 14%.44,45,50,51 Poor 
patient compliance may be due to ankle discomfort, 
noise generation, and sleep disturbance.51 
pharmacological prophylaxis
Pharmacological prophylactic agents include 
aspirin, warfarin, LMWH, and newer agents such 
as dabigatran and rivaroxaban (Fig.). These agents 
are all recommended by the ACCP.36 Nonetheless, 
controversies exist regarding which the most 
appropriate agents are, the optimal treatment 
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duration, and the need to use them especially in 
populations with low risk of VTE.
The need for pharmacological prophylaxis in Asian 
populations
VTE rates were thought to be low in Asian 
populations.52,53 In 1970s, autopsy studies on Chinese 
indicated that the incidence of PE was 0.75%, and that 
of lower-limb DVT was 18%.54 The incidence of DVT 
in Hong Kong Chinese receiving surgery for fractures 
of the proximal femur was 53% on the operated side 
and 14.3% on the normal side.55 In the SMART study, 
the DVT rate was 36.5% in Asians having total joint 
replacement.19 In Japanese patients, the DVT rate was 
65.3% after TKR and 33.8% after THR.20 In our hospital, 
the PE rate was 0.5%, of which one fifth (0.1%) were 
fatal.56 Nonetheless, pharmacological prophylaxis 
is not routinely used in many Asian countries. The 
DVT rates in Japanese THR patients receiving 
placebo, LMWH, or synthetic pentasaccharide were 
not significantly different.57 Mechanical prophylaxis 
alone is considered adequate in Japanese patients.57,58 
However, there are limitations in these conclusions. 
The mean time to develop DVT is about 22 days,59 
but in one study outcome was measured on day 11 
using duplex ultrasonography and thus may not be 
representative.57 The other study was a retrospective 
review of medical records and only symptomatic 
VTE was analysed (asymptomatic DVT was not 
detected).58 Asymptomatic DVT is associated with 
post-thrombotic syndrome and recurrent DVT and 
should be prevented if feasible.60
 According to the Asia-Pacific Thrombosis 
Advisory Board, the risk of VTE in Asian patients 
is clinically significant.33 The advisory board 
recommends anticoagulation as the main preventive 
strategy for VTE following total joint replacement.
Aspirin
Aspirin is an inhibitor of the COX enzyme system.61 
There are 2 COX isoenzymes (COX1 and COX2) 
and aspirin inhibits COX1 more than COX2. COX1 
is chiefly expressed on platelets and is responsible 
for the synthesis of prostaglandin H2, which later 
becomes thromboxane A2. Without thromboxane A2, 
platelets cannot aggregate and thrombus cannot form. 
Using aspirin is definitely contraindicated in patients 
with allergy to non-steroidal anti-inflammatory 
drugs. Its should also be used with caution in patients 
with renal impairment or gastrointestinal bleeding.61
 Aspirin is mildly effective for the prevention of 
VTE. Meta analysis showed that aspirin was effective 
in reducing the rate of DVT to 30.6% from 48.5%.13,41 
Aspirin is inferior to warfarin or LMWH in terms of 
preventing symptomatic PE or proximal DVT.13,43 
 Earlier editions of the ACCP guideline 
recommended against the use of aspirin as the sole 
prophylactic agent after total joint replacement.35 
The first edition of AAOS guideline recommended 
aspirin as one of the prophylactic agents,34 because 
the occurrence of symptomatic or fatal PE in the 
aspirin group was as low as that in the LMWH or 
warfarin groups.13,62–64 In addition, aspirin has the 
lowest risk of bleeding complication among all the 
pharmacological agents.13 This is important because 
bleeding and formation of haematoma are associated 
with postoperative infection, and an infected joint is 
considered the most disastrous complication. Aspirin 
can offer effective prophylaxis when combined with 
mechanical prophylaxis.65–70 Aspirin is one of the 
pharmacological agents in the latest edition of the 
ACCP guideline36 and in the second edition of the 
AAOS guideline.71
 Aspirin is an effective antithrombotic agent at 
doses of 50 to 1500 mg daily.72 The lowest effective 
daily dose for various vascular disorders such as 
ischaemic stroke (50 mg daily) or angina (75 mg 
daily) was well established, but this was not the case 
in VTE. The venous system has slower flow than the 
arterial system, and thus a higher dose of aspirin 
(around 325 mg daily) is needed to prevent VTE.65–70
 If a more potent anticoagulant is used instead 
of aspirin, prevention of DVT is more effective but 
at higher risk of bleeding complications. If aspirin 
is used alone, symptomatic or fatal PE remains 
rare and bleeding complication is less likely, but 
asymptomatic DVT may progress to post-thrombotic 
syndrome. Thus, aspirin should be used as part of 
multi-modality treatment.
Warfarin
Warfarin is a vitamin K antagonist. Vitamin K is an 
essential substrate of liver enzymes responsible for 
the final synthesis of clotting factors II, VII, IX, and 
X. Warfarin inhibits the maturation of these factors 
in the coagulation cascade.73 Excessive intake of 
dietary vitamin K, which is mainly contained as 
phylloquinone in green vegetables reduces the 
anticoagulant effect of warfarin.73 Warfarin should 
be used cautiously in patients taking aspirin or other 
non-steroidal anti-inflammatory drugs, because 
of the increased risk of gastrointestinal bleeding. 
Warfarin also interacts with several commonly used 
medications, including antibiotics, proton pump 
inhibitors, and cholecystaramine.73 The anticoagulant 
effect can either be counteracted or potentiated, 
because of alterations in intestinal absorption or 
metabolic clearance.
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 Warfarin has been used in total joint replacement 
patients for more than 40 years.74,75 It is more effective 
than aspirin but less effective than LMWH in 
reducing rates of proximal DVT and symptomatic 
PE.13,43 Warfarin is relatively safe in terms of bleeding 
complications. Both the ACCP and AAOS guidelines 
recommended warfarin for VTE prophylaxis.
 Frequent monitoring of the INR is needed. It 
takes a few days to establish an adequate INR. 
Patients started on warfarin should be covered with 
a fast-acting anticoagulant (such as LMWH) for a few 
days after the operation until the therapeutic INR 
is attained. The optimal INR range should be 2 to 
3 according to the ACCP,35,36 and 1.5 to 2 according 
to the AAOS.34 The discrepancy arises because the 
ACCP was based on studies using warfarin as a 
monotherapy,76–78 whereas the AAOS recommended 
a multimodal regimen. When mechanical 
prophylaxis (such as pneumatic compression and 
early mobilisation) is used, an INR of 1.5 to 2 is 
effective.79,80 Higher INR values are associated with 
higher rates of postoperative bleeding complications 
and infection.81–83
Low-molecular-weight heparin
LMWHs are fragments of heparin produced by 
chemical or enzymatic depolymerisation. They 
have a lower affinity than standard heparin for 
von Willebrand Factor and thus produce less 
bleeding.84 LMWHs have longer plasma half life 
and more predictable anticoagulant response than 
standard heparin, enabling less frequent injection 
and monitoring. LMWHs work by binding to 
antithrombin III through a unique pentasaccharide 
sequence. This binding leads to a conformational 
change in antithrombin III and markedly accelerates 
its ability to inactivate thrombin and factor X.84
 LMWH has the highest efficacy in terms of 
preventing VTE.13,14,43 The ACCP recommends the use 
of LMWH in preference to other agents.36 However, 
LMWH is also associated with complications related 
to wound drainage, haematomas, thrombocytopenia, 
and injection.13,85–88 Compared with warfarin, LMWH 
further reduces the DVT rate to 29% (from 45%) in 
TKR patients and to 18% (from 23%) in THR patients; 
the rate of fatal PE is reduced to 0.04% (from 0.16%).43 
However, the rate of clinically significant bleeding 
increased from 1.67% to 2.22%.13 This is a concern 
because wound haematomas are associated with 
postoperative infection.82,83
 A high dose (30 mg every 12 hours) of LMWH 
(enoxaparin) results in frequent bleeding episodes.85–87 
The dose-response effect is well-recognised; the 
complication rate can be reduced if a lower dosage 
is used. Together with mechanical prophylaxis, the 
dosage of LMWH can be reduced while retaining the 
same efficacy.89–91 
Dabigatran
Thrombin is an enzyme in the coagulation cascade 
responsible for converting fibrinogen to fibrin 
and stimulating platelet aggregation. Dabigatran 
is an oral thrombin inhibitor. A drug from the 
same family named ximelagatran was superior to 
warfarin, but was withdrawn from market because 
of hepatotoxicity.92 Dabigatran 150 or 220 mg daily is 
as effective as LMWH (enoxaparin) 40 mg daily when 
given for at least 6 days to TKR patients and at least 28 
days to THR patients.93–95 Higher dosage is associated 
with more bleeding complications.96 Thus the optimal 
regimen of dabigatran should be 150 to 220 mg daily. 
In Asian patients, it is 110 to 220 mg daily.97
 Gastrointestinal absorption of dabigatran 
is fast, but can be reduced if co-administered 
with a proton pump inhibitor. Maximal plasma 
concentrations of dabigatran can be reached within 
6 hours of administration.98 Routine coagulation tests 
(prothrombin time, activated partial thromboplastin 
time, and INR) are altered in patients receiving 
dabigatran, but the results are highly variable and 
poorly reflect the circulating plasma concentration.99 
Regular monitoring of coagulation is therefore not 
recommended.
 Dabigatran has a satisfactory safety profile and 
does not cause any organ toxicity. It is not metabolised 
by the cytochrome P450 enzyme system,100 and has 
low potential for drug interaction. Over 80% of drug 
elimination was through the kidneys; elderly patients 
or those with impaired renal function should receive 
a smaller dose (≤150 mg daily).101 
 Owing to the fast onset of action of dabigatran and 
its long half life (12 to 13 hours in elderly patients), 
the timing of removal of epidural catheters on day 2 
becomes challenging. 
Rivaroxaban
Factor X is an important enzyme in the coagulation 
cascade. Activated Factor X (Xa) is responsible for 
converting factor II to thrombin. Rivaroxaban is an 
oral Factor Xa inhibitor. It has an inhibitory effect on 
thrombin and tissue factor.102 Similar to dabigatran, it 
can be given postoperatively and routine monitoring 
is not necessary.99 In the RECORD programme, 
rivaroxaban (10 mg daily) was compared to 
enoxaparin (40 mg daily).32 When given for at least 
11 days in TKR patients and 30 days in THR patients, 
rivaroxaban was more effective than enoxaparin in 
reducing the risk of symptomatic VTE and all cause 
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mortality. Nonetheless, the rate of major bleeding 
was not significantly different. Rivaroxaban is at 
least as effective as enoxaparin in VTE prophylaxis 
in THR and TKR patients without increasing the risk 
of bleeding.103
 When compared with tinzaparin (another 
LMWH), rivaroxaban resulted in more wound 
problems including clinical signs of wound infection 
or haematoma (1.8 vs 3.9%), but infection rates 
were similar.104 Further clinical trials are needed to 
evaluate the safety and efficacy of rivaroxaban. The 
timing to remove the epidural catheter in patients on 
rivaroxaban is also not yet settled.
timing of prophylaxis
The mean time for VTE to occur was 21.5 days after 
THR and 9.7 days after TKR.59 DVT and PE occurred 
at a median of 21 and 34 days respectively after 
THR, and at a median of 20 and 12 days respectively 
after TKR.105 10 days of thromboprophylaxis 
after TKR and up to 35 days for THR patients are 
recommended.106 The ACCP recommends extending 
thromboprophylaxis for up to 35 days for all joint 
replacement patients.36 The AAOS does not state 
the duration of prophylaxis and suggests surgeons 
discussing this with their patients.37
 As the risk of VTE extends beyond the usual 
length of hospitalisation, oral prophylaxis should 
be provided after discharge. LMWH requires 
subcutaneous injection, whereas aspirin, warfarin, 
dabigatran, and rivaroxaban can be taken orally once 
daily, and for the latter 2 routine monitoring is not 
needed.
Multimodal prophylaxis
Combining mechanical and pharmacological 
prophylaxis enables reduction of the dosage of 
anticoagulants and thus the risk of bleeding, and 
achieving the same or even better thromboprophylaxis 
than monotherapy.43,107,108 There are numerous 
multimodal prophylaxis regimens (differing in 
combination, dosage, and duration) involving pre-, 
intra-, and post-operative measures. Preoperative 
measures include discontinuation of procoagulant 
medication and autologous blood donation. Intra-
operative measures include administration of 
hypotensive epidural anaesthesia, intravenous 
heparin, aspiration of intramedullary contents, 
elastic stocking, and pneumatic compression of the 
non-operated limb. Postoperative measures include 
early mobilisation and pharmacological prophylaxis 
(oral warfarin or aspirin for 4 to 6 weeks). In a study 
using multimodal prophylaxes, the incidence of DVT 
was only 2.8% and of non-fatal PE was 0.6%. There 
was no instance of fatal PE. The rate of bleeding 
complication was also low, and no patient underwent 
surgical drainage of any wound haematoma.109
 In a study combining the use of epidural 
anaesthesia, intra- and post-operative exercises, 
elastic stocking or intermittent compression, and 
aspirin, the rate of clinical DVT was only 0.64% and 
that of non-fatal PE was 0.18%, whereas wound 
haematoma developed in 0.2% of patients.110 In 
another study combining the use of low-dose 
warfarin (target INR, 1.5–2), pneumatic compression 
during the in-patient period, and elastic compression 
stocking after discharge, the rate of clinical DVT was 
only 0.2% and that of non-fatal PE was 0.1%, whereas 
wound haematoma developed in 0.4% of patients.80
 Classifying patients into low or high risk of 
developing VTE is advocated.90 Low-risk patients 
received aspirin and intermittent calf compression, 
whereas high-risk patients received LMWH or 
warfarin and intermittent calf compression. All 
patients were allowed mobilisation within 24 hours 
of surgery. There was no fatal PE. The overall rate 
of clinical DVT was only 0.4% and of PE was 0.25%. 
Wound haematoma occurred in only 0.4% of patients. 
The 2 groups were not significantly different. The use 
of less potent pharmacological prophylaxis agent for 
low-risk patients and the use of more potent agent for 
high-risk patients was effective.90
 The addition of intermittent mechanical leg 
compression augments the efficacy of anticoagulants 
in preventing DVT.111 The ACCP guideline 
recommends using dual prophylaxis with an 
antithrombotic agent and an intermittent pneumatic 
compression device during the hospital stay.36 
The AAOS guideline also adopts a multimodal 
approach which incorporates pre-, intra-, and post-
operative measures.37 Preoperatively, the risk of VTE 
(history of thromboembolism) and bleeding (known 
bleeding disorder or active liver disease) should 
be determined. Intra-operatively, in consultation 
with the anaesthesiologist, regional anaesthesia 
is preferred. Postoperatively, a combination of 
mechanical prophylaxis, early mobilisation, and 
pharmacological prophylaxis is recommended.
conclusion
Appropriate prophylaxis of VTE aims to balance risks 
and benefits. Asian populations are not free from 
VTE, and prophylaxis should be given. In patients 
with no increased risk of bleeding, a multimodal 
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prophylaxis regimen combining both mechanical 
and pharmacological agents offers the best outcome 
while minimising complications. Aspirin (325 mg 
daily), warfarin (targeting INR of 1.5 to 2), LMWH 
(enoxaparin 20 to 40 mg daily), dabigatran (110 to 
220 mg daily) and rivaroxaban (10 mg daily) are all 
appropriate pharmacological agents. The duration of 
prophylaxis should be 35 days. Oral anticoagulants 
are preferred after discharge. 
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